Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIENTATE: Decitabine in KRAS-dependent PDAC
NCT05360264Phase 2Terminated
- Start
- Jan 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine in pancreatic ductal adenocarcinoma (PDAC). Started Jan 2022; status: terminated.
02
Drugs
decitabine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05360264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05360264.